BRISBANE, Australia,
June 26, 2017 /PRNewswire/ -- At
the Metabolomics Society Meeting 2017, Bruker announces a new
solution for the quantification of metabolites in urine using
Nuclear Magnetic Resonance (NMR). Urine metabolic analysis is
particularly valuable and information-rich, because the metabolic
pathways of a wide range of nutrients, drugs and environmental
contaminants can be identified in urine, even if urine is very
complex to analyze. The new B.I.QUANT-UR™
module of Bruker's successful Avance® IVDr
(In Vitro Diagnostics research) 600 MHz NMR platform now
provides precise, sensitive and fully reproducible results that
have demonstrated great potential in preclinical animal and
clinical/translational research.
Urine is an important body fluid in metabolomics due to little
interference with metabolite binding proteins. Large sample
cohorts in clinical studies demand automated solutions capable of
measuring and analyzing with highest information content and
quantitative reproducibility. The new B.I.QUANT-UR module is a completely
automated solution that can replace multiple conventional analysis
methods.
Bruker's Avance IVDr platform is optimized for
clinical and translational research. It uses standard
operating procedures (SOPs) in B.I.Methods to
automatically generate highest quality spectra, with full
quantitative reproducibility and lab-to-lab transferability, from
urine measurements. This ensures the highest quantitative precision
and reliability of analytical and statistical results, at a
throughput of approximately 80-100 urine samples in 24
hours. Access to the Bruker Data Analysis server provides
automated remote analysis.
Professor Claudio Luchinat at the
University of Florence, a
co-founder of the Magnetic Resonance Center (CERM),
commented: "Metabolite quantification in human urine has
proven a challenging task due to complex compositional changes from
test person to test person, and even from the same person at
different time points. Wet spiking methods according to DIN-norm to
detect the limit of detection (LOD) are not delivering sufficient
information for safe quantification." He continued to explain:
"With innovative Bruker NMR validation tools it is possible to
break this barrier. The new routines introduced for urine
quantification also take into account substantial matrix changes
going from neonates to children/adults, which all affect metabolite
chemical shifts and lead to varying overlap situations due to ionic
matrix changes in these two different age classes. We are directly
engaged with Bruker in the project to optimize NMR shift
prediction."
Dr. Iris Mangelshots, President
of Bruker BioSpin's Applied, Industrial & Clinical (AIC)
division, confirmed: "Bruker continues to innovate with the
introduction of novel and performance-leading NMR solutions for
translational research markets at the Metabolomics Society Meeting
2017. There is an increased demand of technologies being able
to analyze large numbers of samples due to increased cohorts in
clinical studies. NMR is an established tool for obtaining
metabolic phenotypes. This is further evidence of expanding of
our analysis support providing automatic quantification of a
variety of metabolites in urine directly after the measurement. The
automated quantification is based on in-house developed algorithms
involving fitting predefined proton 1D NMR signals, with optional
2D NMR confirmation of identification."
B.I.QUANT-UR can
quantify up to 150 metabolic compounds, including disease markers
and non-targeted classification against healthy newborn models,
opening new areas of research in frequent diseases such as
diabetes, metabolic syndrome and obesity. Additonally, the
tool can be used to investigate the role which nutrition and
environmental conditions play in health, including functional food
efficiency and drug dosage. The IVDr profiling modules
B.I.QUANT are for
research use only and are not released for clinical
diagnostics.
For more information:
www.bruker.com/products/mr/nmr-preclinical-screening
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, and in
microscopy, nano-analysis and industrial applications. In recent
years, Bruker has also become a provider of high-performance
systems for cell biology, preclinical imaging, clinical phenomics
and proteomics research, clinical microbiology, and for molecular
pathology research. For more information: www.bruker.com.
Media
Contact:
|
Investor
Contact:
|
Thorsten Thiel,
Ph.D.
|
Miroslava
Minkova
|
VP of Group
Marketing
|
Head of Investor
Relations
|
Bruker BioSpin
Group
|
Bruker
Corporation
|
T: +49 (721)
5161–6500
|
T: +1 (978) 663-3660,
ext. 1479
|
E:
thorsten.thiel@bruker.com
|
E:
miroslava.minkova@bruker.com
|
SOURCE Bruker Corporation